CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-339

Currently, EYE is essentially a one product enterprise but that product has the potential of becoming the gold standard in the treatment of glaucoma going forward. The top end of the market (where the smart money resides) largely focuses on risk that is ultimately a function of operational diversification. This may be one of the reasons for the tardy EYE share price activity of late but that can change in a heartbeat particularly if there are performance metrics that provide confirmation of market status that is or will in the near future provide the returns forecast from such a product. My feeling is that EYE is currently in a transition phase where nothing has been actually confirmed in respect to its performance sustainability yet certainly implied in the distribution and sales data so far. Sometimes it takes time and patience to reach the critical mass point but usually when it does, the investment capital finds it and that is when the re rating of EYE will occur IMHO.